AUAUniversity Podcast Series: Episode No. 70

GU Podcast (2020): The Expanding Role Of Immune Checkpoint Inhibitors In MIBC And NMIBC

The Expanding Role of Immune Checkpoint Inhibitors in MIBC and NMIBC
At the conclusion of this activity, participants will be able to:

  1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer.
  2. Describe the mechanism of action of immunotherapy regimens.
  3. Identify and manage the adverse events related to these agents.

This educational series is supported by independent educational grants from:

Astellas
AstraZeneca
Bristol Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Merck
Pfizer, Inc
Sanofi Genzyme
UroGen Pharma, Inc.